Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis vs on‐demand therapy
Proportion with zero bleeds · people without inhibitors
Summary of findings table ‐ Emicuzimab 3.0 mg/kg bi‐weekly prophylaxis showed no clear difference in proportion of participants with zero bleeds compared with on‐demand therapy (low certainty).
1 finding from 1 review
- Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B 2024 · Cochrane Headline outcomes onlyRR 15.31 [0.96, 242.76]1 study · 53 participantsLow